B+
Bull case
25%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
SLS
SELLAS Life Sciences GroupDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
SELLAS has two potentially material AML milestones: REGAL final analysis after the 80th event and SLS009 Phase 2 topline data expected in Q4 2026. The Q2 company release reported $138.3 million of cash and cash equivalents, a $9.6 million quarterly net loss, and $6.3 million of quarterly R&D expense, while management highlighted preparation for a potential GPS BLA and preclinical PDAC optionality [#SEC-8K-2026-08-11].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.0.
What can break
Clinical development spending and future financing or dilution may pressure per-share value despite $138.3 million of cash and cash equivalents.
Momentum
98
Value
41
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.50 · Bull $25.00 · Bear $4.50Analysis 2026-08-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-13 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $32.50
Why
Momentum98 · Δ7d -1.3
Value41 · Δ7d -0.0
Sentiment52 · Δ7d +4.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +4.0.
Contradictions & invalidation
- • Clinical development spending and future financing or dilution may pressure per-share value despite $138.3 million of cash and cash equivalents.
- • Market-reaction evidence is limited to qualitative secondary headlines rather than a verified causal price analysis.
- • The investment case remains binary and efficacy has not yet been disclosed.
Catalyst clock
2026-11-11
REGAL Phase 3 reaches the 80th-event trigger and proceeds to topline analysis
Lead driver: Sentiment · See AI snapshot
Momentum
98
9% active weight
Current posture
7d trendSoftening
Δ7d
-1.3
Δ21d
-0.9
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
52
62% active weight
Current posture
7d trendImproving
Δ7d
+4.0
Δ21d
-1.1
Why this grade
Composite grade D. Momentum 97.8 / Value 41.2 / Sentiment 51.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-13. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.63B
Beta
2.27
Shares Out
201.95M
P/E (TTM) · Derived
-52.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-68.89
Rev YoY
-100.0%
EPS YoY
-24.2%
Gross Margin
+44.3%
Op Margin
-
Net Debt
-$70.89M
Current Ratio
18.83
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data